15 Result(s)
-
Article
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Chronic urticaria (CU) is a skin disorder characterized by the recurrent eruption of short-lived wheals accompanied by redness and itching for at least 6 weeks. The wheals can be associated with angioedema. CU...
-
Article
Chronic Spontaneous Urticaria: the Emerging Role of Coagulation
Chronic urticaria (CU) is a cutaneous disease characterized by the recurrent eruption of short-lived wheals for at least six weeks. The wheals, which are surface swelling of the dermis accompanied by itching, ...
-
Article
Open AccessManagement of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net
Langerhans Cell Histiocytosis (LCH) is an orphan disease of clonal dendritic cells which may affect any organ of the body. Most of the knowledge about the diagnosis and therapy is based on pedriatic studies. A...
-
Article
Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweet’s Syndrome: a Comprehensive Review and Disease Classification Criteria
Pyoderma gangrenosum (PG) and Sweet’s syndrome (SS) are skin diseases usually presenting with recurrent ulcers and erythematous plaques, respectively. The accumulation of neutrophils in the skin, characteristi...
-
Article
Pathomechanisms of Chronic Spontaneous Urticaria: What Is Known and Up to Date
The pathomechanism of chronic spontaneous urticaria (CSU), defined by the recurrence of short-lived wheals for more than 6 weeks without apparent triggers, remained to be mysterious until 1986. In that year, s...
-
Reference Work Entry In depth
Langerhans Cell Histiocytosis, Skin
-
Article
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis usually manifesting as skin ulcers with undermined erythematous-violaceous borders. It may be isolated, associated with systemic conditions or occurring i...
-
Article
A Comprehensive Review of Neutrophilic Diseases
Neutrophilic dermatoses are a group of conditions characterized by the accumulation of neutrophils in the skin and clinically presenting with polymorphic cutaneous lesions, including pustules, bullae, abscesse...
-
Article
Extracutaneous involvement of pyoderma gangrenosum
Pyoderma Gangrenosum (PG) is an inflammatory neutrophilic dermatosis (ND) associated with underlying chronic inflammation and/or malignancy. Diagnosis remains to be challenging as a gold standard diagnostic te...
-
Reference Work Entry In depth
Langerhans Cell Histiocytosis, Skin
-
Article
Pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly develo**, painful skin ulcers hallmarked by undermined borders and peripheral erythema. Epidemiological studies indicate...
-
Article
Open AccessPyoderma Gangrenosum: Treatment Options
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomen...
-
Article
Open AccessCorrection to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History
-
Article
Open AccessAtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History
AtopyReg® is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST)....
-
Article
Open AccessLong-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of...
